Dispatches from Vitafoods Europe 2014

Omega-3’s newest big fish reveals sector ambitions

Loading the player...

Mid-last year the chief of Norwegian omega-3 player EPAX told us, “We are the last of the big omega-3 independents.” Soon after US agri-food company FMC had snapped it up for $350m. Here FMC Nutraceuticals general manager Daniel H. Rosenbaum talks through the ‘how’ and the ‘why’ of the move…and the ‘where’ it might lead.

“The opportunity to take a position in omega-3 – particularly a premium position – was really one that fit our growth ambitions quite well,” he said.

Rosenbaum discusses omega-3 formulation, regulation, science and more here and why it is looking to further invest in health and wellness.

The omega-3 sector has seen serious consolidation in recent years with acquisitions including Martek Biosciences (DSM, €830m), Ocean Nutrition Canada (DSM, €430m) and Pronova Biopharma (BASF, €690m).

Related News

Red Queen theory argues that despite inducing greater and more speedy responses from rivals, the most active and aggressive firms are the best performers.

Red Queen Rules: Understanding nutra space acquisition and evolution

FMC has been disappointed by the demand for its concentrated omega-3 products.

FMC sells pectin division to Cargill, signals concern about omega-3s business

FMC set for Danish innovation centre boost

FMC set for Danish innovation centre boost

FMC to split into two publicly traded companies

FMC to split into two publicly traded companies

FMC said its Seal Sands omega-3s production facility will start shipping products in the first quarter of 2014.

FMC posts earnings, says UK omega-3s facility nearing full scale production

Mike Smith: 'Our microcrystalline cellulose is already used by some of the biggest brands in supplements so we’re excited about being able to talk to them about omega-3s'

FMC: 'We looked at the omega-3 area broadly and it was clear Epax was the premier property in this space'

FMC seals $345m deal to buy omega-3 expert Epax

FMC Corporation makes bold move into omega-3 market with $345m deal to buy Epax

Epax chief Ola Snove: “We can move faster and have the capacity to be better partners than the giants. We are specialists – we only do omega-3.”

Epax chief: ‘We are the last of the big omega-3 independents’

Related Products

See more related products